- Home
- CELC vs SITC Comparison
CELC vs SITC Comparison
Compare CELC & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- SITC
- Stock Information
- Founded
- CELC 2011
- SITC 1965
- Country
- CELC United States
- SITC United States
- Employees
- CELC N/A
- SITC N/A
- Industry
- CELC Medical Specialities
- SITC Real Estate Investment Trusts
- Sector
- CELC Health Care
- SITC Real Estate
- Exchange
- CELC Nasdaq
- SITC Nasdaq
- Market Cap
- CELC 440.0M
- SITC 494.6M
- IPO Year
- CELC 2017
- SITC 1993
- Fundamental
- Price
- CELC $55.07
- SITC $8.74
- Analyst Decision
- CELC Strong Buy
- SITC Buy
- Analyst Count
- CELC 5
- SITC 7
- Target Price
- CELC $53.60
- SITC $30.29
- AVG Volume (30 Days)
- CELC 862.3K
- SITC 1.0M
- Earning Date
- CELC 11-13-2025
- SITC 10-29-2025
- Dividend Yield
- CELC N/A
- SITC 54.41%
- EPS Growth
- CELC N/A
- SITC N/A
- EPS
- CELC N/A
- SITC 6.74
- Revenue
- CELC N/A
- SITC $173,351,000.00
- Revenue This Year
- CELC N/A
- SITC N/A
- Revenue Next Year
- CELC N/A
- SITC $2.31
- P/E Ratio
- CELC N/A
- SITC $1.27
- Revenue Growth
- CELC N/A
- SITC N/A
- 52 Week Low
- CELC $7.58
- SITC $8.69
- 52 Week High
- CELC $63.06
- SITC $18.15
- Technical
- Relative Strength Index (RSI)
- CELC 59.21
- SITC 27.51
- Support Level
- CELC $50.44
- SITC $8.92
- Resistance Level
- CELC $63.06
- SITC $9.09
- Average True Range (ATR)
- CELC 3.03
- SITC 0.25
- MACD
- CELC -0.90
- SITC -0.21
- Stochastic Oscillator
- CELC 44.24
- SITC 1.22
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.